In a new study examining treatment responses to enzalutamide in men with metastatic castration-resistant prostate cancer, enzalutamide following abiraterone acetate resulted in lower PSA responses and shorter progression-free survival times compared with treatment-naive patients. Cytotoxic therapy might be the better approach for patients failing first-line antihormonal treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).
Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).
Cheng, H. H. et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. http://dx.doi.org/10.1038/pcan.2014.53.
Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).
Heidenreich, A., Pfister, D., Merseburger, A., Bartsch, G. & German Working Group on Castration-Resistant Prostate Cancer (GWG-CRPC). Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur. Urol. 64, 260–265 (2013).
Sonpavde, G. et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol. Oncol. 30, 607–613 (2012).
Fizazi, K. et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.10.001.
van Soest, R. J. et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann. Oncol. 26, 743–749 (2015).
Karantanos, T. et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 67, 470–479 (2015).
Buettner, R., Wolf, J. & Thomas, R. K. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J. Clin. Oncol. 31, 1858–1865 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Heidenreich, A., Pfister, D. Sequencing AR-targeted agents might be ineffective in mCRPC. Nat Rev Urol 12, 246–247 (2015). https://doi.org/10.1038/nrurol.2015.81
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.81
